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S U M M A R Y
Objective: The hepatitis E virus (HEV) is a leading cause of acute hepatitis in developing countries and an
emerging pathogen in Europe. HEV seroprevalence has rarely been assessed in cohorts of travelers, and
previous studies have reported a very low rate of exposure. We assessed HEV seroprevalence in French
expatriate workers.
Methods: The prevalence of HEV IgG and IgM was assessed among 43 French expatriate workers using
two commercial microplate enzyme immunoassays (Adaltis and Wantai). Additionally HEV IgG-positive
sera were tested with an immunoblot assay (recomLine), while IgM-positive sera were tested with a
rapid immunochromatographic assay (Assure).
Results: The prevalence of anti-HEV IgG was 3.7 times higher in French expatriates than in comparable
blood donors from the same area. A discrepancy was evidenced between the HEV IgG results obtained by
the Wantai and Adaltis assays (48.8% vs. 30.2%).
Conclusions: Expatriation from France, including to areas not recognized as hyperendemic for HEV, may
expose individuals to HEV infection. This issue warrants further study; in particular, serology should be
compared before and after travel. The most sensitive Wantai serological assay should be used for
epidemiological studies to obtain better insight into the epidemiology of HEV.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The hepatitis E virus (HEV) is hyperendemic throughout
tropical and subtropical countries, with epidemic and sporadic
cases involving genotypes 1 and 2 viruses.1 In 2005, HEV genotypes
1 and 2 accounted for an estimated 20.1 million HEV infections, 3.4
million symptomatic cases, 70 000 deaths, and 3000 stillbirths.2 In
developed countries, HEV infection is far more common than
previously recognized. An increasing number of sporadic autoch-
thonous cases have been reported, which have implicated HEV
genotypes 3 and 4.3 Acute HEV infection has been reported
previously in travelers from developed countries, mainly when
returning from hyperendemic areas, but HEV infection has
accounted for a very low proportion of diseases observed in
cohorts of international travelers.4* Corresponding author. Tel.: +33 (0)4 91 96 35 35/36; fax: +33 (0)4 91 96 89 38.
E-mail address: philippe.gautret@club-internet.fr (P. Gautret).
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http://dx.doi.org/10.1016/j.ijid.2013.06.013To challenge the hypothesis of frequent asymptomatic HEV
infections in travelers, we investigated the seroprevalence of HEV
in a cohort of French expatriate workers who frequently stayed
abroad.
2. Methods
A total of 43 expatriate workers from a 65-employee company
based near Marseille that provides overseas services related to
submarine pipelines and coastal works were prospectively
included in the study from February 2011 to May 2012. Employees
who had already completed missions abroad at the time of
inclusion were selected when they consulted for systematic
screening for travel-associated diseases at our hospital. Subjects
underwent routine blood sampling for anti-HEV antibody testing
and completed a standard questionnaire to collect data related to
their travel history over the last 10 years.
We tested serum samples for both HEV IgG and IgM antibodies
using two commercial enzyme immunoassays (Adaltis andses. Published by Elsevier Ltd. All rights reserved.
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IgG- or IgM-positive according to either assay with an immunoblot
assay and an immunochromatographic rapid test and an in-house
real-time PCR assay,5 respectively.
3. Results
Comparative analyses of serum samples from these 43
individuals showed 13 serum samples (30.2%) to be positive for
anti-HEV IgG with the Adaltis assay and 21 serum samples (48.8%)
to be positive for anti-HEV IgG with the Wantai assay (Table 1). The
two assays were concordant for 70% (30/43) of the serum samples.
After secondary testing, 10/13 (77%) of the Adaltis-positiveTable 1
Anti-hepatitis E virus (HEV) IgG and IgM and HEV RNA detection in serum samples wi
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sample
number
Anti-HEV IgG
detection
by Adaltisa
MEIA (ODR)
Anti-HEV IgG
detection
by Wantaib
MEIA (ODR)
Anti-HEV IgG
detection by
immunoblotc
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de
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ME
1 1.5 5.1 +  
2 1.6 6.7 +  
3 1.8 14.8 ++  
4 1.9 15.0 ++ 3.4
5 1.9 13.1 +++ 7.4
6 2.2    
7 2.4 6.9 + 1.3
8 3.2 14.0 ++ 1.5
9 3.7 1.8 ++  
10 5.3 11.1 ++ 1.9
11 6.6 3.9   
12 6.7 12.9 +++  
13 6.8    
14   ND  
15   ND  
16   ND  
17   ND  
18     
19   ND  
20  1.0   
21  7.3 ++  
22  4.2  3.3
23     
24   ND  
25   ND  
26   ND  
27  7.3 ++  
28   ND  
29   ND  
30  9.2 ++ 1.5
31  5.9   
32  5.6 ++  
33     
34     
35  10.7   
36   ND  
37  8.5 +  
38  5.4   
39  13.7 +++ 2.8
40   ND  
41   ND  
42   ND  
43   ND  
Ig, immunoglobulin; MEIA, microplate enzyme immunoassay; ODR, test threshold optica
density ratio (ODR) >1.1, negative for ODR <0.9, and within the gray zone for ODR >0.9 an
of IgM and IgG in the absence of HEV RNA indicated a recent infection, and the presen
a Adaltis EIAgen kits (Casalecchio Di Reno, Italy).
b Wantai assays (Wantai Biologic Pharmacy Enterprise, Beijing, People’s Republic of 
c Immunoblot assay (recomLine HEV IgG Mikrogen GmbH, Martinstried, Germany): 
d Immunochromatographic rapid test (IRT; Assure, HEV IgM MP Diagnostics, Genela
e In-house real-time PCR assay.samples and 16/21 (76%) of the Wantai-positive samples were
positive by immunoblot.
Anti-HEV IgM was detected in the serum of eight people using
the Adaltis assay and two using the Wantai assay. The two assays
provided correlative anti-HEV IgM results for 82% (35/43) of the
serum samples. In the secondary testing, 2/8 (25%) Adaltis-positive
sera and 2/2 (100%) Wantai-positive sera were conﬁrmed by the
immunochromatographic assay. HEV RNA testing was negative for
all of the serum samples. There was one individual who had
diarrhea and liver cytolysis.
Overall, the percentage of individuals with a serology indicating
past (anti-HEV IgG alone) or recent HEV infection (IgM and IgG in
the absence of HEV RNA) was 39.5% (17/43) (Table 1).th any assay
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l density ratio; ND, not done; , negative. Results were positive for test/cutoff optical
d <1.1. The detection of anti-HEV IgG alone indicated a past infection, the detection
ce of HEV RNA indicated an on-going infection.
China).
+++ strong positivity; ++ intermediate positivity; + weak positivity.
b, Singapore).
Table 2
Demographics, travel history, health and vaccination status, risk factors, and
potential exposure to hepatitis E virus of the expatriate worker cohort
Age, mean (range) 35.7 years (24–63 years)
Gender (F/M) 7/36
Occupation
Engineer 22 (51%)
Technician 12 (28%)
Administration staff 9 (21%)
Overall duration of expatriation over the last 10 years according to the levels of
endemicity for the hepatitis E virusa
Highly endemic 10.9 months (0–43.8 months)
Endemic 3.1 months (0–21.3 months)
Non-endemic 8.27 months (0–58 months)
All areas 22.2 months (1–76.8 months)
Mean duration of stay per mission 3.1 months (0.3–9.3 months)
Mean number of missions over the last 10 years9 (1–34)
Number of missions according to travel region
North Africa 105 (27.4%)
Southeast Asia 56 (14.6%)
Central Africa 50 (13.1%)
West Asia 33 (8.6%)
Oceania 31 (8.1%)
West and North Europe 28 (7.3%)
Number of stays per country (top 6)
Indonesia 45
Morocco 43
Cameroon 33
Libya 31
Algeria 25
New Caledonia 21
Past history of hepatitis (laboratory conﬁrmed)
Hepatitis Ab 3 (7%)
Hepatitis Bc 2 (4.6%)
Hepatitis Cd 1 (2.3%)
Vaccination status (laboratory conﬁrmed)
Hepatitis A 21 (48.8%)
Hepatitis B 34 (79%)
Chronic diseasese 6 (13.9%)
Occasional alcohol consumption 25 (58.1%)
F, female; M, male.
a See http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-dis-
eases-related-to-travel/hepatitis-e.htm
b Anti-hepatitis A virus IgG-positive without vaccination.
c Anti-hepatitis B core and anti-hepatitis B surface antibody-positive, anti-
hepatitis B surface antigen-negative.
d Anti-hepatitis C virus IgG-positive.
e Past carcinoma (n = 2), asthma (n = 2), rheumatoid arthritis treated with
methotrexate (n = 1), heart disease (n = 1).
M. Vernier et al. / International Journal of Infectious Diseases 17 (2013) e1082–e1084e1084A total of 383 stays were recorded for the last 10 years for all of
the individuals. Most of the missions were located in North Africa
and Southeast Asia (Table 2).
4. Discussion
HEV seroprevalence has rarely been assessed in cohorts of
travelers, and these studies have reported no or very few HEV
seroconversions, with the prevalence of HEV IgG ranging from 0 to
4%.6–8 This is in contrast to the high seroprevalence observed in ourcohort. HEV IgG prevalence in French overseas workers was 3.7
times higher than in normal blood donors living in the same
geographical area9 and approximately 2.7 times higher than in
kidney or liver transplant recipients,10 as determined by the same
assay (Adaltis). Although these ﬁndings were obtained by
comparing different populations, they indicate that traveling
abroad for long periods of time may be associated with an
increased exposure to HEV. In the present study, most of the HEV-
seropositive individuals did not exhibit any clinical symptoms,
which suggests that most HEV infections are likely asymptomatic;
this is congruent with previous reports.
The sample size of our cohort is small and results cannot be
extrapolated to all travelers. Further studies are needed to
determine the incidence rate of HEV infection in large cohorts of
individuals who frequently work overseas by comparing HEV
serological patterns before and after travel. Because hepatitis E can
be fatal, these studies may be helpful in identifying countries and
behaviors that represent risks for HEV infection. Additionally,
these studies would help to determine if such special populations
of travelers could beneﬁt from speciﬁc preventive measures.
Finally, in the present study, we found a large discrepancy to
exist between the HEV IgG results obtained by the Wantai and
Adaltis assays, and the higher prevalence rate found with the
Wantai assay is considered very unlikely to represent false-
positive results.10 These data prompt the use of the most sensitive
Wantai serological assay to obtain better insight into the
epidemiology of HEV.
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